Keywords: astrazeneca, buy, remainder, cat, premium, europe, third-largest
AstraZeneca to buy remainder of CAT, but at a 67% premium
Article | 22 May 2006
AstraZeneca, Europe's third-largest pharmaceutical company, plans to acquire the remaining 80.1% of fellow UK-based Cambridge Antibody Technology that it does not ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
